English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Why You Don't Inject Psilocybin: A Cautionary Tale About Magic Mushrooms
There's a case study floating around medical journals that anyone curious about psilocybin should probably read before they do anything else. A man in Nebraska, mid-thirties, struggling with bipolar disorder and trying to taper himself off opioids, decided to brew magic mushrooms into a tea — and then inject the tea directly into his bloodstream. He ended up in the ICU for three weeks. The fungi, it turned out, were still alive. They grew inside him. This is not a story I tell to be lurid. I tell it because the conversation around psychedelics has shifted so fast in the last few years that a lot of people are walking into plant medicine with enthusiasm but very little grounding. The research on psilocybin for depression, anxiety, and addiction is genuinely promising. The cultural momentum behind psychedelic healing is real. But the gap between what these substances can do in a supported setting and what they do when someone improvises alone at home is enormous. And occasionally fatal. The basics are these. The man had untreated bipolar I and had stopped his medication. During a manic phase, he read online about psilocybin as a possible tool for reducing opioid dependence. Somewhere in his research he made a leap that nobody in the legitimate psychedelic-medicine world would ever make: he decided injection would be more effective than swallowing. He boiled dried mushrooms, strained the liquid through a cotton swab, and pushed it into a vein. Within days he was vomiting blood, jaundiced, confused, and his organs were shutting down. Doctors found his liver damaged, his kidneys failing, and — the detail that made the case famous — Psilocybe cubensis spores germinating and multiplying in his bloodstream. He needed a ventilator, blood filtration, antibiotics, and antifungals. He stayed alive. Many people in that situation wouldn't. The case got written up in the Journal of the Academy of Consultation-Liaison Psychiatry. It's now cited in harm-reduction trainings around the world for a very simple reason: it illustrates, in the most extreme way possible, what happens when the method of administration is wrong, the setting is wrong, and the person taking the medicine is in a fragile psychiatric state with nobody watching. If you're reading this, you're probably not planning to inject anything. Good. But the deeper lesson here isn't just about needles. It's about the assumption that because a substance is natural, or because it shows up in promising clinical trials, you can figure it out on your own. Master plants — ayahuasca, psilocybin mushrooms, San Pedro, iboga, peyote — have been used in structured ceremonial contexts for centuries, sometimes millennia. Those contexts exist for reasons that go beyond ritual aesthetic. Dosage, preparation of the body, screening for medical and psychiatric contraindications, the presence of an experienced guide, the integration period afterward — all of that scaffolding is what makes the difference between healing and harm. Strip it away, and you're not doing plant medicine. You're doing a chemistry experiment on yourself. The man in Nebraska wasn't reckless because he was curious about psilocybin. He was reckless because he tried to treat a serious psychiatric condition during an active manic episode, without medical oversight, using a method he invented. Any one of those factors alone would be a red flag at a reputable retreat. All three together is the kind of thing that lands you on a ventilator. This is one of the most-searched questions in the whole psychedelic space, and it's worth answering honestly. The short version: yes, there's real evidence, and it's getting stronger every year. Johns Hopkins has run trials showing psilocybin's effect on tobacco addiction with results that beat anything pharmaceuticals have managed. NYU and other institutions have studied it for alcohol use disorder, depression in cancer patients, and treatment-resistant depression. The early data is striking. But here's the part the headlines tend to skip. Every one of those trials uses pharmaceutical-grade psilocybin, screened participants, two trained therapists in the room, preparation sessions before, and integration sessions for weeks after. The drug itself does some of the work. The container does the rest. Take away the container and you're left with a powerful psychoactive substance and a person who may or may not be ready for what it shows them. This is why the better retreats — the ones genuinely worth your time — look more like clinical programs than vacations. They want your medical history. They ask about medications, especially SSRIs and lithium and MAO interactions. They want to know your psychiatric background. If they don't ask, that's the red flag, not a good sign. If the Nebraska case made you wary, that's healthy. It should also make you more careful about choosing where to go if you do decide a retreat is right for you. A few things to look for: None of this guarantees a good experience. Plant medicine is unpredictable by nature. But these basics filter out the operators who are running tourist traps or, worse, the ones who have no idea what to do when something goes sideways at 3 a.m. Beyond extreme cases like injection, there are subtler risks that most enthusiastic retreat-goers underestimate. Psilocybin and ayahuasca can both destabilize people with personal or family histories of psychosis, schizophrenia, or bipolar disorder. The Nebraska man's bipolar diagnosis was relevant before the needle ever came into the picture — psychedelics during a manic phase are a known accelerant. Drug interactions matter too. SSRIs can blunt the experience or, in the case of MAO inhibitors and ayahuasca's harmala alkaloids, create serious cardiovascular danger. Lithium plus psychedelics has triggered seizures. Even cannabis, which a lot of people don't think of as a drug at all, can interact unpredictably during or after a ceremony. And then there's the psychological aftermath, which gets less attention than it deserves. People come home from intense psychedelic experiences with their normal coping patterns dismantled and not much in place yet to replace them. The first few weeks are tender. Some people experience what looks like depression as old material surfaces. This is normal and often part of the healing arc, but it needs support to move through. Going back to a job and a relationship and a life that hasn't changed, with no one to talk to, is how good experiences turn into difficult ones. The reason stories like the Nebraska case stick with me isn't the horror of the medical details. It's the loneliness behind them. A man in distress, trying to help himself, working from internet fragments, with no one around to say wait, that's not how this works. The tragedy isn't that he tried psilocybin. It's that he had nobody to do it with him properly. If something has drawn you to plant medicine — addiction you can't shake, a depression that doesn't lift, a sense that you're stuck in patterns you didn't choose — that pull is worth honoring. Just honor it the right way. Talk to your doctor. Be honest about your medications and your mental health history. Take time to research facilitators rather than booking the first retreat that comes up on Google. Read accounts from people who've been through it, the difficult ones as well as the glowing ones. For readers who want to take the next step thoughtfully, a curated selection of vetted psilocybin and ayahuasca retreats can be browsed on our marketplace here. The point isn't to rush — it's to find a setting where the medicine has a chance to do what it's actually capable of, in a container built by people who know what they're doing.
Psychedelics, Addiction, and the Quiet Return of Plant Medicine to Medicine
Somewhere around three in the morning inside a Navajo tepee, a roadman is singing in Diné, a deerskin drum is keeping time, and a couple at the center of the circle is weeping through their troubles. Peyote is being passed in a worn bowl. Nobody is chasing visions. They're trying to get through something — together. That scene, described decades ago by a journalist who'd been invited in by a Harvard psychiatrist, captures something the renewed wave of psychedelic enthusiasm often misses: the medicine is rarely the whole story. That's worth holding onto when you're scrolling through ayahuasca retreat websites at midnight, wondering if plant medicine might finally crack open the depression, addiction, or stuck pattern you can't seem to budge on your own. Psychedelics are real. The research is real. The risk is real too. And the context — who's running the ceremony, what you bring into it, what you do after — matters as much as the brew itself. Research on psychedelics in the 1950s and 60s was genuinely promising. Clinicians were exploring LSD for alcoholism, psilocybin for end-of-life distress, mescaline for understanding consciousness. Then the substances escaped the lab, the cultural backlash arrived, and by the early 1970s most of that research had been shut down. Nearly all of it. For about thirty years, serious clinical work on these compounds was essentially frozen. What's changed since the late 1990s is that researchers — including psychiatrists with very mainstream credentials — quietly began running rigorous studies again. Some looked at peyote use in the Native American Church and found, somewhat to the surprise of skeptics, that long-term ceremonial users showed cognitive function comparable to non-users, plus better measures of life satisfaction and mental health. Others started examining MDMA for PTSD, psilocybin for depression, and ibogaine for opioid addiction. The work is still early. But it's no longer fringe. If you've been hearing more about ayahuasca and psychedelics in the last couple of years, that's not just media hype. It's the slow reemergence of a research field that lost three decades and is trying to catch up. This is the question I get asked most often, usually in a quieter voice than the other questions. Someone in their late thirties has tried meetings, tried rehab, tried therapy, tried white-knuckling, and is now wondering if a week in the jungle drinking ayahuasca might do what nothing else has. The honest answer is: maybe, but not the way people imagine. Plant medicines aren't a magic erase button. What participants and clinicians describe is something more like a hard reset — a chance to see the addiction from outside, to feel the wound underneath it, to access grief or shame that's been locked away, and to imagine being someone who doesn't need the substance. That experience, when it happens, can be a powerful pivot point. It's not a cure on its own. A few things tend to be true of the people who get the most out of these experiences for recovery: Ibogaine, in particular, has a striking track record with opioid dependence. People describe an extraordinarily long experience — sometimes more than 24 hours — that often interrupts withdrawal symptoms and gives them a clear window to rebuild. It also carries real cardiac risk and requires medical screening. This is not a substance to take in someone's spare bedroom. Reputable ibogaine clinics run ECGs, check liver function, and have a doctor on site. If the place you're considering doesn't, walk away. The term master plants comes from Amazonian tradition. It refers to plants — ayahuasca, tobacco (mapacho), San Pedro, chacruna, and others — that are understood within those traditions as teachers. Not metaphorically. Literally. A curandero will tell you that the plant has things to show you, and your job is to listen. You don't have to share that worldview to take it seriously. What you do need to understand is that traditional ceremonies are built around this premise, and the people guiding them are working within a framework that has its own logic, its own protocols, and its own internal accountability. A dieta — the period of restricted food, social isolation, and connection with a specific plant — isn't a wellness trend. It's a discipline practiced for centuries. This matters when you're choosing a retreat. There's a meaningful difference between a center where Shipibo or Quechua curanderos are leading ceremony in their own tradition, and a center where a Western facilitator with three years of training is improvising something that looks the part. Neither is automatically better or worse for every person, but you should know which one you're booking. People want this question answered honestly and almost nobody does, so here's the closest I can get. The first hour of an ayahuasca ceremony is often the hardest. The brew tastes terrible — bitter, earthy, like swamp water with notes of disappointment. Then you wait. Maybe forty minutes in, things start to shift. Geometry, colors, a sense of something underneath the surface of things. Then, often, nausea. The purge — vomiting, sometimes crying, sometimes both — is considered part of the medicine, not a side effect to be avoided. From there, what unfolds is impossible to generalize. Some nights are gentle. Some nights are excavations. People meet their grief, their younger selves, their parents, their fears about death. Some encounter what they describe as beings, or as the plant itself. Some get nothing and feel cheated and then have a breakthrough the next night. It is not a recreational experience. By hour four, most people in the maloca are too busy to remember why they thought this would be fun. By morning, there's often a strange quiet. People drift out, drink water, sit in hammocks, don't talk much. The work, in many ways, is just beginning. This is the section retreat brochures skip, and it's the most important one. Plant medicines aren't for everyone, and a responsible facilitator will turn people away. If they don't screen you carefully, that itself is a red flag. The standard cautions, from clinicians who've worked with these substances for decades: Pregnancy is another clear no. Recent serious head injury, another. Be radically honest on intake forms. The retreat isn't trying to trip you up; they're trying to keep you alive. A few practical filters that have served me and the people I've sent in this direction: And trust your gut. If something about the place feels off in the email exchange — defensive, vague, weirdly aggressive about money — that signal will not improve once you're on site. The ceremony is not the work. The ceremony is the opening. The work is what happens in the weeks and months after, when the insights start to fade and your old patterns come knocking with their luggage. Integration looks like therapy, journaling, somatic practice, community, time in nature, changes to who you spend time with, changes to how you spend your evenings. It's slow. It's mostly invisible from the outside. And it's where the actual healing — if there's going to be any — gets cemented. People who skip this part often end up chasing the next ceremony, then the next, hoping the experience itself will do the work. It won't. The plants, if they're teachers, are pointing at something. You still have to walk over and look at it. If you've read this far, you're probably not looking for a sales pitch — you're looking for a thoughtful next step. For readers who want to take this further, a range of vetted ayahuasca, ibogaine, and psilocybin retreats can be browsed on our marketplace here. Whatever you decide, go in with clear eyes, an honest history, and someone at home who knows where you are.
Why Venture Capital Is Pouring Into Psychedelic Medicine (And What It Means for Retreats)
Something strange is happening at the intersection of finance and plant medicine. The same people who used to put money into biotech start-ups and cannabis brands are now writing cheques to companies developing psilocybin therapies, synthetic 5-MeO-DMT, and ayahuasca-adjacent treatments for depression, addiction, and trauma. If you've been quietly researching whether a psychedelic retreat might help with something stuck in your own life, this matters more than it might look. Here's why: the money flowing into clinical research is changing the conversation around psychedelics from fringe spiritual practice to credible mental health intervention. That shift affects everything — the legal landscape, the kind of people booking ceremonies, the safety standards retreat centres are starting to adopt, and the way insurance companies and doctors talk about plant medicine. Whether you find that exciting or unsettling probably depends on where you sit. Maybe both. Let's unpack what's actually going on, what the research is showing, and what any of it has to do with you sitting in a maloca in Peru drinking a bitter brown brew. A few years ago, the idea of a venture fund dedicated entirely to psychedelics would have sounded like a joke at a dinner party. Today there are dozens of them. Funds in London, Berlin, Toronto, and New York are scouting biotech start-ups working on psilocybin, ibogaine analogues, DMT delivery systems, and ketamine clinics. Some have raised tens of millions. A few of the companies they back have gone public on the Nasdaq. The driver is brutally simple: mental illness is the most expensive health crisis on the planet. Estimates put the global cost at trillions of dollars a year once you factor in lost productivity, healthcare burden, and the human side that doesn't show up on a spreadsheet at all. Conventional antidepressants help some people some of the time. They fail a lot of people. Therapy is expensive and rationed. Into that gap walks a class of compounds that, in early trials, are doing things SSRIs simply cannot do — particularly for treatment-resistant depression, PTSD, end-of-life anxiety, and certain addictions. If you're an investor, that's a market. If you're a person who has tried three antidepressants and still can't get out of bed, that's a maybe-finally. The headline finding from the past several years of psilocybin research is that a small number of guided sessions — often just one or two — can produce sustained reductions in depression and anxiety scores months later. That's not how pharmaceuticals usually work. SSRIs require daily dosing and weeks to kick in. Psilocybin, in the trial settings, behaves more like a catalyst than a maintenance drug. Similar signals are emerging in other corners of the field: None of this is settled science. Trials are small. Placebo effects are notoriously hard to control for when participants can obviously tell whether they've been dosed. Long-term safety data is still thin. But the pattern is consistent enough that serious researchers at serious institutions are no longer hedging the way they did a decade ago. If you came to this article because you or someone you love is wrestling with addiction, pay close attention to this section. Of all the conditions psychedelics are being studied for, addiction may be where they have the most distinctive contribution to make. Conventional addiction treatment is largely behavioural — meetings, counselling, harm reduction, sometimes maintenance drugs like methadone or buprenorphine. It works for many people. It also has high relapse rates, and it tends to address the surface behaviour rather than what's underneath it. For a lot of people in recovery, the question that haunts them isn't how do I stop but why do I keep coming back to this thing that's killing me. Plant medicine seems to act on exactly that layer. Ayahuasca, ibogaine, psilocybin — in different ways and with different intensities, they tend to surface the emotional and biographical material that addiction has been managing. People report seeing, sometimes for the first time, what they've been numbing. That's brutal. It's also, for many, the first time the underlying knot has been visible enough to start untying. None of this means psychedelics are a magic bullet. Ibogaine in particular carries real cardiac risk and should never be taken outside medically supervised settings. People with serious cardiovascular conditions, certain psychiatric histories, or who are on SSRIs face genuine danger. But for the right person in the right setting, the evidence is increasingly hard to dismiss. Here's where the venture-capital story circles back to the person reading this on their phone at midnight, wondering whether to put down a deposit on an ayahuasca retreat. The research funding doesn't directly change what happens in ceremony. The shamans aren't on anyone's payroll. The vine still grows in the Amazon. The icaros are still sung the way they've been sung for generations. But the cultural permission structure around retreats is shifting fast. Five years ago, telling a colleague you were going to Peru to drink ayahuasca would have raised eyebrows. Now it's a conversation people have at dinner parties without anyone choking on their wine. That cultural shift is partly the work of the researchers and the investors — they've made it respectable to say in public that these substances have therapeutic potential. The practical downstream effects you might notice as a retreat-seeker: Some of this is genuinely good. Better screening saves lives. Integration support is the difference between a difficult night becoming a turning point and a difficult night becoming a wound. Some of it is more complicated — the medicalisation of plant medicine has critics who argue that stripping out the indigenous context strips out the part that actually heals. If you're weighing whether to book somewhere, the investment boom doesn't really change the questions you should be asking. It just means there are more options, at more price points, with more varied philosophies. A short checklist that's served people I've spoken with well: Price is not a reliable signal of quality. Some of the most respected centres in the Amazon charge a fraction of what a polished European retreat costs. Some of the expensive ones are excellent. Some are essentially wellness theatre. Do the homework. It would be irresponsible to write this much about psychedelic medicine without naming what it isn't. It isn't a guaranteed cure for anything. People go to retreats hoping for a single ceremony that will undo decades of pain and sometimes come home disappointed, or worse, destabilised. The experiences can be physically punishing. They can surface material you weren't ready for. They can interact badly with psychiatric medications. They are not appropriate for people with personal or family histories of psychosis or bipolar disorder. The legal situation in your home country probably matters more than the marketing copy suggests. Most psychedelics remain illegal in most jurisdictions, even when the research is promising. The retreats operating legally tend to be in countries — Peru, Costa Rica, Jamaica, the Netherlands, Mexico — where specific substances exist in legal grey or green zones. That's why the retreat industry exists where it does. And finally: the venture-capital story is a real one, but it's not the only story. Indigenous communities have been working with these plants for centuries without anyone's IPO. The medicine doesn't need permission from a fund manager in London to do what it does. If you decide to go, you're stepping into a tradition that long predates the spreadsheet. If something in all of this resonates and you'd like to take a closer look at what's actually available, a curated range of ayahuasca and psychedelic retreats can be explored on our marketplace here. Read carefully, ask questions, and take your time — this isn't a decision to rush.
Santa Cruz Decriminalized Psilocybin and Ayahuasca: What It Means for Plant Medicine
Santa Cruz is a small coastal city, the kind of place where the surfers outnumber the office workers and the bookstores still sell hand-printed zines. So it tracks, weirdly, that it became one of the first cities in the United States to formally pull back the policing of psilocybin mushrooms, ayahuasca, and peyote. The city council voted unanimously to make personal use, possession, and cultivation of natural psychedelics among the lowest priorities for local law enforcement. That single vote — quiet, unflashy, passed in a council chamber most people will never set foot in — said something larger about where the country is heading on plant medicine and master plants. Ayahuasca, psilocybin, San Pedro, peyote: substances that have been used ceremonially for centuries are being reconsidered as legitimate tools for addiction recovery, treatment-resistant depression, and the kind of stuck-life patterns that ordinary therapy sometimes can't budge. If you've been quietly researching a retreat, or wondering whether the legal landscape is shifting fast enough to matter, this is the kind of decision worth understanding. Not because Santa Cruz is going to be your destination — but because it tells you something about the direction of travel. The resolution doesn't legalize anything. That's the first thing worth being clear about. What it does is instruct local police to deprioritize investigations and arrests of adults 21 and over who are using, possessing, or growing entheogenic plants and fungi for personal use. Commercial activity — selling, trafficking — is still on the table for enforcement. The list of covered substances is specifically natural: psilocybin mushrooms, ayahuasca, peyote, ibogaine-containing plants, and other plant or fungal preparations with psychoactive compounds. Synthetic compounds like LSD and MDMA aren't included, which is consistent with how Denver and Oakland framed their earlier moves. The distinction matters because the case for decriminalization here leans heavily on the idea that these are traditional medicines with deep cultural lineage, not lab inventions. What does that mean on the ground? Practically, it means a Santa Cruz resident growing a few mushroom jars in their closet is unlikely to face local prosecution. It does not mean they can legally sell them, advertise them, or operate a retreat center. Federal law also still classifies psilocybin and DMT (the active alkaloid in ayahuasca) as Schedule I, so the federal picture hasn't budged. Denver got there first, in 2019, after a grassroots campaign that nobody outside Colorado expected to succeed. Oakland followed a month later with a broader resolution covering all entheogenic plants and fungi. Santa Cruz made three. Within a few years, the list grew to include Washington D.C., several Massachusetts towns, Detroit, and others — and Oregon voters went further still, approving regulated therapeutic psilocybin use statewide. The arguments driving these votes tend to cluster around three points. First, there's the medical research — and there's now a serious amount of it. Johns Hopkins, Imperial College London, NYU, and others have published studies showing meaningful results for treatment-resistant depression, end-of-life anxiety, smoking cessation, and alcohol use disorder. A 2017 study in Nature Scientific Reports found nearly half of patients with treatment-resistant depression showed positive responses five weeks after psilocybin sessions. Numbers like that get policymakers' attention in a way that anecdotal testimony doesn't. Second, there's the cultural lineage argument. Ayahuasca has been part of Amazonian healing for generations. Peyote is sacrament in the Native American Church. Psilocybin mushrooms appear in Mesoamerican religious practice going back centuries. Framing prohibition as a relatively recent and culturally narrow imposition makes the policy easier to unwind. Third — and this is the one that resonates most with readers I've spoken to — there's the addiction question. Conventional treatment for addiction works for some people and fails badly for others. Plant medicine for addiction recovery, particularly ibogaine for opioid dependence and ayahuasca for various substance disorders, has produced results striking enough that even cautious clinicians are paying attention. Here's where I want to slow down, because the news cycle around decriminalization tends to imply more than it delivers for the person actually weighing a retreat. Decriminalization at the city level changes nothing about your federal risk if you bring substances across borders or transport them between states. It does nothing for the safety of the ceremony you'd actually attend — that depends entirely on the facilitators, the setting, your preparation, and your own medical and psychological readiness. And it does not create a regulated marketplace where you can verify quality or training. In the cities that have decriminalized, you still can't walk into a storefront and book a sanctioned ayahuasca ceremony the way you can in Peru or Costa Rica. For most people serious about a psychedelic retreat for addiction, depression, or trauma work, the realistic options remain: None of these are casual decisions. Each carries its own due diligence — facilitator credentials, medical screening (some SSRIs, MAOIs, and heart conditions are genuinely dangerous with ayahuasca), the ethical record of the retreat center, and what the integration support looks like in the weeks after you come home. The ceremony itself is maybe a third of the work. The preparation and the integration are the rest. The temptation, when you see headlines like Santa Cruz's, is to assume the dam is breaking. It isn't, quite. What's happening is more interesting and more gradual: a steady accumulation of municipal and state-level decisions, combined with FDA breakthrough therapy designations for psilocybin and MDMA, that together signal a slow normalization of psychedelic-assisted therapy as a clinical category. For someone researching a retreat right now, this trend matters for a few practical reasons. Quality is improving as the stigma lifts and more experienced facilitators come out of the shadows. Medical screening protocols are getting more rigorous. Integration services — therapists, coaches, peer groups who specifically work with people coming home from psychedelic experiences — are easier to find than they were five years ago. It also means more people in your life may have already done this, which makes the conversation less awkward. Asking a friend who attended a ceremony two years ago what they wish they'd known is probably the single most useful research step you can take, after honest medical screening. If the Santa Cruz vote nudged you toward looking more seriously, here's the short version of what I'd suggest paying attention to — gathered from too many conversations with people who got it right and people who got it wrong: Plant medicine isn't a guaranteed fix for addiction or depression, and any retreat that promises otherwise should make you nervous. What it can do — when the setting is sound and you've done your part — is open a window onto patterns that have been running your life from below. Whether you can keep that window open afterward depends on the work you do once the ceremony ends. If something here has nudged you to look more seriously at the options, a range of curated ayahuasca and psilocybin retreats from facilitators around the world can be browsed on our marketplace here. Read carefully, ask hard questions, and take your time — the right retreat will still be there next month.
Psilocybin Mushrooms and Human Consciousness: Ancient Roots, Modern Healing
Here's a fact that takes a second to sit with: psilocybin — the molecule responsible for the visions, the ego-loss, the long quiet weeping that people describe after a mushroom ceremony — has been around roughly 65 million years longer than we have. The little brown caps people now line up to take in clinical trials were already making their compound when the dinosaurs were still smoking. We are the newcomers in this relationship, not the mushrooms. That single piece of context changes how the conversation around psychedelics and addiction lands. We aren't inventing anything. We're catching up to something that humans have been working with — ritually, medicinally, carefully — for thousands of years. And the science finally has the tools to ask why it works. A 2024 paper in the Proceedings of the National Academy of Sciences sequenced dozens of Psilocybe species, many of them rare specimens pulled out of museum drawers. The researchers traced the gene cluster responsible for producing psilocybin and psilocin and found two distinct genetic patterns within it. The split between those two lineages happened around 57 million years ago. The capacity to produce the compound itself? Roughly 65 million years old — emerging right around the time non-avian dinosaurs were on their way out. This matters for a few reasons. First, it suggests psilocybin isn't an evolutionary accident. Mushrooms that put energy into building a complex psychoactive molecule presumably got something out of it — possibly defense against insects, possibly something subtler involving the soil microbiome. Second, it confirms that the relationship between fungi and animal nervous systems is ancient and ongoing. Our brains and these molecules co-evolved on the same planet, in overlapping ecological niches, for tens of millions of years. The practical upside of mapping the genetics is that scientists can now study how psilocybin is synthesized at the molecular level. That opens doors for cleaner therapeutic formulations and a better understanding of why slightly different mushroom species produce dramatically different experiences. Long before any of this was in a peer-reviewed journal, the people of Mesoamerica were eating these mushrooms for serious reasons. The Mazatec called them teonanácatl — "flesh of the gods." Archaeological evidence places ceremonial use back at least three thousand years, threading through the Aztec, the Mixtec, and into living traditions you can still encounter today in Oaxaca. This wasn't recreation. Mushrooms were consumed by healers and religious authorities, in specific settings, with specific intentions: contacting ancestors, diagnosing illness, settling grief, asking questions of the unseen. Stone carvings and pre-Columbian codices depict the experience and its spiritual weight. Similar fungal traditions show up on other continents, with different species and different cosmologies but a remarkably consistent thread — the idea that certain mushrooms are teachers, not products. The continuity matters. When something keeps reappearing across unrelated cultures over millennia, it's worth taking seriously even if you don't share the metaphysics. The framing those cultures used — preparation, ceremony, an experienced guide, a return ritual afterward — turns out to track surprisingly well with what current clinical protocols are reinventing under different names. Of all the things modern trials have looked at, the results in addiction recovery are some of the most striking. Studies at Johns Hopkins on smoking cessation have shown abstinence rates that conventional pharmacology can only dream about. Trials for alcohol use disorder have produced sustained reductions in heavy drinking days. Smaller studies have looked at cocaine and opioid use with cautiously promising results. What seems to be happening, mechanistically, is a window of neuroplasticity. Psilocybin temporarily loosens the grip of habitual brain networks — especially the default mode network, which is the chatter-loop most of us live inside. For a few hours, the rigid patterns that keep addiction running on autopilot become negotiable. People often describe seeing their own behavior from outside, without the usual defensiveness. Then comes the hard part: the integration weeks that follow, when those insights either get embedded into daily life or fade back into noise. This is why the substance alone isn't the medicine. A pill in a sterile room is not the same intervention as a held, prepared experience with skilled support before and after. The traditions knew this. The clinical data is now confirming it. None of this means psilocybin is a miracle, and the field has earned the right to be cautious about overpromising. But the signal across independent labs is real, and it's the reason regulators in several countries are quietly rewriting their frameworks. Once you start reading in this area, you bump into theories that sit at the edge of testable science. Some are interesting. Some are pure vibes. Worth knowing the difference. Mycelium — the underground web of fungal threads that Psilocybe species (and most other mushrooms) actually live as — does some genuinely strange things. It conducts electrical signals. It redistributes nutrients between unrelated plants. It responds to damage and threat in ways that look adaptive. Some researchers have argued, half-seriously, that mycelial networks resemble externalized neurological systems. Whether any of this rises to "intelligence" in the sense we mean for animals is a wide-open question. Probably not in the way we usually think about it. Possibly in some other way we don't yet have words for. Then there's Terence McKenna's stoned ape hypothesis — the idea that early hominids eating psilocybin mushrooms on the African savanna got a cognitive boost that helped drive the emergence of language and self-aware thought. It's a great story. It is also almost entirely speculative, with no fossil evidence and significant timeline problems. Treat it as mythology, not science. Mythology can still be useful — it just shouldn't be confused with data. If you've read this far, you're probably not researching mushrooms abstractly. You're trying to figure out whether a psilocybin retreat — in Jamaica, the Netherlands, Mexico, or wherever it's legally accessible — is a reasonable next step for something specific in your life. Depression that hasn't responded to SSRIs. A drinking pattern that's stopped feeling optional. Trauma that talk therapy hasn't moved. A general sense of being stuck. A few honest things to weigh: The mushrooms have been doing this work, in one form or another, since before we existed. The question for anyone considering a retreat in 2026 isn't whether psilocybin "works" — the research has moved well past that. The question is whether your particular situation, your support system, and your reasons for going are aligned enough to make the experience useful rather than disorienting. If something here resonates and you want to look at what's actually available, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The mushrooms aren't going anywhere — they've waited 65 million years already.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
The Science of Psilocybin Therapy: What Mushrooms Actually Do to the Brain
Here's something most people don't realize when they first start reading about psychedelic healing: the mushrooms aren't doing the heavy lifting. The mushrooms crack the door. What walks through it — old grief, buried memory, the version of yourself you've been avoiding for fifteen years — that's the actual work. And the science of psilocybin therapy is finally catching up to what curanderos and underground therapists have quietly known for decades. If you're researching a psilocybin retreat, or wondering whether psychedelics could help with the depression or addiction or stuck pattern that hasn't budged with anything else, you deserve a real answer rather than a glossy one. So let's get into what the research actually shows, what happens in the brain, and what an honest decision-making process looks like before you commit your money and your nervous system to a journey. Psychedelic therapy, at its simplest, is the supervised use of substances like psilocybin, MDMA, LSD, or ketamine in combination with psychotherapy. The substance creates an altered state. The therapist — or a trained facilitator, depending on the setting — helps the person prepare for that state, holds space during it, and then guides the integration afterward. The integration piece is the part people skip in articles, and it's also the part that determines whether you come home changed or just come home with a story. Two broad models tend to show up. The first is psycholytic therapy, which uses smaller, more frequent doses over many sessions. The person stays largely lucid and the therapist works conversationally. The second, and the one most modern clinical trials are built around, is high-dose therapy — one to three big sessions, eyeshades on, curated music in the headphones, minimal talking. The facilitator's job is mostly to keep you safe so your own psyche can do what it needs to do. What makes this approach different from standard psychiatry is the durability of the results. Three sessions. Sometimes one. That's not how SSRIs work. That's not how years of weekly talk therapy work. Something else is happening here, and researchers are finally allowed to ask what. For decades, the research was effectively frozen. After the cultural collision of the late 1960s, psilocybin landed on Schedule I in the United States and the labs went dark. The last few years have changed that. Institutions like Johns Hopkins and Imperial College London have been quietly producing studies that read less like cautious science and more like a slow-motion paradigm shift. The headline findings cluster around a few areas — treatment-resistant depression, end-of-life anxiety, addiction (especially nicotine and alcohol), obsessive-compulsive disorder, and PTSD. The effect sizes in these trials are, to put it plainly, unusual. We're not talking about a 10% improvement over placebo. We're talking about studies where the majority of participants experience meaningful, sustained change after a small number of sessions. A 2016 Johns Hopkins study gave psilocybin to patients with life-threatening cancer who were struggling with depression and existential dread. Roughly 80% reported a significant reduction in both depression and anxiety, and the effect held for at least six months. Many described what they'd seen as the most personally meaningful experience of their lives — ranked alongside the birth of a child or the death of a parent. That's not a sentence you read in clinical literature very often. A smaller 2014 Johns Hopkins study looked at psilocybin paired with cognitive behavioral therapy for people trying to quit smoking. Fifteen participants. Two or three high-dose sessions. At the twelve-month follow-up, 67% were still cigarette-free. For context, the best pharmaceutical smoking-cessation drugs hover around 35% at six months and drop from there. The number isn't a fluke — it's been replicated in extended follow-ups — and it suggests something important about how psilocybin works on addiction at a level deeper than nicotine cravings. When researchers at Imperial College London first put people on psilocybin into fMRI scanners, they expected to see the brain light up. Psychedelic, more activity — seemed obvious. The opposite happened. Activity in a region called the default mode network actually went down. The default mode network is the brain's autopilot. It's the chatter that runs when you're not focused on a task — the planning, the worrying, the rehearsing of conversations you'll never have. It's also where most neuroscientists think the sense of self, the ego, gets constructed. When psilocybin quiets it, the result is what people across cultures have been describing for thousands of years: ego dissolution, the sense that the boundary between self and everything else has gone soft. That softening is the therapeutic mechanism. With the ego less in charge, material that's been locked away — trauma, grief, shame, the story you tell yourself about who you are — can surface and be reconsidered. The brain also forms unusual new connections during the experience, with regions that don't normally talk to each other suddenly in conversation. Some researchers describe it as the snow globe of your psyche being shaken so the patterns can settle differently. Psilocybin isn't operating alone in this field. Several other substances — many of them traditional master plants used by indigenous cultures for centuries — are showing similar therapeutic promise. Each of these works differently. Each carries its own risks, its own ceremonial lineage (or lack of one), and its own integration demands. Treating them as interchangeable is one of the more common mistakes people make when they're new to this space. Psilocybin remains illegal in most jurisdictions, though that's shifting. Oregon and Colorado have established legal therapeutic frameworks. Retreats operate legally in the Netherlands (where truffles containing psilocybin are permitted), Jamaica, and parts of Mexico. Clinical trials exist for those who qualify and can wait. Before you book anything, the questions worth sitting with: Public opinion on psychedelics has shifted faster in the past five years than in the previous fifty. Michael Pollan's writing brought the conversation into living rooms it had never reached before. The FDA has granted breakthrough therapy designation to psilocybin for treatment-resistant depression. Clinical trials are expanding into Alzheimer's, anorexia, chronic pain, and grief. None of that means psychedelic therapy is a solved problem. It isn't. There are people for whom these substances are genuinely contraindicated — anyone with a personal or family history of psychosis or bipolar disorder, for starters. There are bad trips that aren't transformative, just bad. There are retreats that take your money and send you home raw with nothing to land on. And there's a quiet phenomenon researchers are starting to name: the spiritual bypass, where people use big experiences to skip over the unglamorous, daily work of actually changing their lives. Still, what's emerging from the labs and the long-running ceremonial traditions is pointing in the same direction. Used carefully, in the right setting, with real preparation and real integration, these medicines can move things that nothing else moves. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — the mushrooms have been around for a few million years and will wait.
Psilocybin for Cancer Anxiety: One Man's Clinical Trial Story
Most people who sign up for a psilocybin trial aren't chasing a high. They're chasing relief — from a diagnosis, from years of grinding anxiety, from the slow erosion that chronic illness does to a person's relationships. That was true for one of the early participants in the now-famous Johns Hopkins and NYU psilocybin studies, a sailor and longtime cancer patient who walked into a treatment room one cold December morning hoping a single dose of a psychedelic might loosen something twenty years of medicine hadn't touched. His story, which has been told in various forms over the years, is worth revisiting because it captures something important about the current wave of psychedelic healing — what the experience can actually feel like, why it isn't a magic bullet, and how the real work tends to begin after the drug wears off. If you're researching a psilocybin retreat or weighing plant medicine for depression or trauma, this is the kind of first-person account worth sitting with before you book anything. The diagnosis came the same year his daughter was born. What followed was the kind of medical marathon that swallows lives: six surgeries, experimental treatments, thousands of appointments, an unspoken vigilance about the next scan. The cancer never fully went away, but it never fully won either. Doctors kept catching it on the edge of spreading. The body survives that. The inner life often doesn't. By the time he was in his late fifties, he was carrying a deep, low-grade depression and a persistent anxiety that had quietly rerouted his attention away from the people he loved. He and his daughter — the baby who'd been born the year his world cracked open — barely spoke. Relationships across the board had thinned out. He'd spent two decades managing a disease, and somewhere in there, he'd stopped being fully present for the rest of his life. This is a pattern anyone who has lived with chronic illness, addiction, or long-term trauma will recognize. Survival mode is a closed loop. You don't notice how small your world has become until something jolts you out of it. In 2010 he read a magazine piece about a trial giving psilocybin — the active compound in psychedelic mushrooms — to cancer patients struggling with depression and existential dread. He reached out. After weeks of questionnaires, interviews, and screening, he was accepted. That study, run jointly at Johns Hopkins and NYU, has since become one of the most cited pieces of psychedelic research, with results striking enough that some clinicians have compared a single guided psilocybin session to a kind of surgical intervention for the mind. The Hopkins treatment room looked less like a hospital and more like someone's living room. Soft lighting, a couch, a stereo, two trained guides who would stay with him the entire time. He swallowed a pill with a glass of water — neither he nor the guides knew yet whether it was psilocybin or placebo — pulled an eye mask over his face, lay back, and waited. It started badly. Within minutes he felt panic climbing up his chest. He tried to meditate it down. That made it worse. There was no off switch — the drug was in him, time had gone strange, and the more he reached for control, the more it slipped. He described the feeling using the language of a sailor. Years earlier, a wave had knocked him off his boat in open ocean. By the time he surfaced, the boat had drifted out of reach. The terror of that moment — boat gone, then water gone, then self gone — was exactly what the early stage of the trip felt like. A full-blown panic attack felt one breath away. His guides did what good guides do. They didn't try to talk him out of the fear. They sat with him, reminded him he was safe, let him know they weren't going anywhere. Slowly, the panic loosened its grip. What replaced it was harder to describe — a kind of timeless ease, a sense of being a witness to his own life rather than a hostage of it. He recalled being in a cathedral-like space, asking to be spoken to. And for the first time in a very long while, he didn't feel alone. People expect psychedelic stories to end with fireworks. They usually don't. The most honest accounts describe a subtle reorientation that becomes obvious only in hindsight. For him, the shift showed up in his relationships. He'd spent years approaching other people as a problem to manage — How do I come across? Am I listening well enough? What should I say next? Coming down from the trip, he noticed a different possibility: that connection is mostly spontaneous if you're actually present for it. That insight wasn't new — therapists and contemplatives have been saying it for centuries — but something about the psilocybin let it land in a place where it could stick. He's been clear, in the years since, that the drug didn't fix him. It cracked something open. The real changes — the slow rebuilding with his daughter, the way he showed up at work, the way he listened — happened over months and years of acting differently because he'd briefly glimpsed a different way of being. He calls the trip a kick-start. A catalyst. Not a cure. If you're considering psilocybin, ayahuasca, or another psychedelic retreat for depression, anxiety, addiction, or trauma, his experience offers a few honest lessons worth holding onto: The current research landscape is genuinely promising. Trials at Hopkins, NYU, Imperial College London, and elsewhere keep showing meaningful reductions in depression and end-of-life anxiety after just one or two guided sessions. Psilocybin, MDMA, ibogaine, and ayahuasca are all under active study for addiction, PTSD, and treatment-resistant depression. None of this means a retreat is right for you. It means the question is worth taking seriously. A few practical things to weigh before you put money down. What's the facilitator's training, and where did they get it? Who handles a medical emergency if one happens? What integration support is included after the ceremony — and is it actually scheduled, or just a vague promise? Are there other participants, and how many? What's the screening process for medications and mental health history? If a retreat brushes these questions off, that's the answer you needed. The man at Johns Hopkins didn't go looking for a mystical experience. He went looking for a way out of a loop that twenty years of standard medicine couldn't break. What he got wasn't a miracle — it was a few hours of strange, hard, occasionally beautiful inner work, followed by years of integrating what he'd seen. That's closer to the real shape of psychedelic healing than the social-media version most people encounter first. If something in this story resonates and you want to look at concrete options, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The retreats worth attending will still be there next month.
What Drinking Ayahuasca Actually Feels Like: An Honest Account
Ask anyone who's actually done it, and you'll get the same long pause before they answer. Drinking ayahuasca isn't something you summarize at a dinner party. The brew has been making its way out of the Amazon and into Western conversation for decades now, but the gap between what people imagine and what actually happens in ceremony is enormous. If you're reading this because you're weighing whether to fly to Peru, Costa Rica, or somewhere closer to home for a retreat, you deserve a straight account — not a sales pitch and not a fever dream. So let's talk about it plainly. What does ayahuasca taste like? What does it do to your body? What does it do to your mind? And what, honestly, is the point — especially if you're someone quietly hoping a plant medicine might help with addiction, depression, or a pattern in your life that won't budge? Ayahuasca is a brew. That sounds obvious, but it's worth saying because a lot of newcomers picture a pill or a powder. It's a dark, syrupy liquid, traditionally simmered for hours — sometimes a full day — over a wood fire in the Amazon. The two main ingredients are the Banisteriopsis caapi vine (the ayahuasca vine itself) and the leaves of the chacruna shrub, though some traditions use other admixture plants. The vine contains MAO inhibitors. The chacruna contains DMT. Neither does much on its own when taken orally — your stomach would shut the DMT down before it ever reached your brain. Together, though, they unlock something that indigenous peoples of the Amazon basin figured out long before any chemistry textbook explained why it works. That's part of what makes the brew remarkable. It's a piece of pharmacology that emerged from a rainforest with tens of thousands of plant species, somehow combined in exactly the right way. Across the upper Amazon — Peru, Colombia, Ecuador, Brazil — ayahuasca is woven into healing traditions that go back generations. It's considered one of the master plants: teacher plants believed to carry intelligence, to instruct the people who drink them. You don't have to subscribe to that worldview to take it seriously. Plenty of skeptical, secular people walk into a ceremony and come out describing things they can't explain. Here's the part nobody glamorizes. It tastes terrible. Picture earth, bark, bile, and stewed coffee grounds, all warmed up. Some people compare it to swamp water. Others say burnt molasses. The point is: you don't sip ayahuasca for the flavor. You drink the cup the facilitator hands you, you set it down, and you wait. The first twenty to forty minutes are quiet. Maybe you feel a slight buzz, a heaviness in your limbs, a shift in how sounds register. Then the icaros — the sung medicine songs — begin, and somewhere underneath them, the brew starts working. People describe it differently: The purging — vomiting, sometimes diarrhea — is part of it. Western readers tend to flinch at this. In the Amazonian tradition, it's not a side effect. It's the medicine doing what it came to do, clearing what it considers ready to leave. Almost every retreat hands you a personal bucket. You'll use it. So will the person next to you. The choreography of a ceremony includes a fair amount of quiet retching, and somehow it becomes ordinary within about twenty minutes. This is the part that's hardest to describe, because language is built for ordinary experience and ayahuasca isn't ordinary. Some people see visions — jaguars, snakes, lattices of color, vast architectures of light. Others don't see much at all and instead are walked through their own memories with a clarity that's almost unbearable. A childhood scene you hadn't thought about in thirty years suddenly arrives in HD, and you understand something about it you'd never understood before. The recurring theme in honest accounts isn't fireworks. It's confrontation. Ayahuasca tends to show people what they've been avoiding. The drinker who came in hoping for cosmic union with the universe might instead spend six hours examining how they've been treating their partner. The person who came for relief from depression might be shown the specific moment, decades back, where the depression set up shop. It can be brutal. It can also be tender — many people report being held, comforted, taught. There's an old joke in this world: ayahuasca gives you what you need, not what you want. Funny because true. This is the question I get most often, and it deserves a careful answer. The short version: there is real, growing evidence that ayahuasca and other psychedelics can support addiction recovery — but it's not a magic eraser, and the people who do best treat the ceremony as the beginning of work, not the end of it. Studies out of Brazil, Canada, and Spain have followed people who used ayahuasca in ceremonial contexts and tracked reductions in problem drinking, cocaine use, and tobacco dependence. Clinical trials with psilocybin for alcohol use disorder have shown encouraging results. Ibogaine, another plant-derived psychedelic from West Africa, has decades of underground use treating opioid addiction, with some clinics now operating legally in Mexico and Costa Rica. What seems to happen, across these substances, is twofold. First, there's a neurological reset — the brain becomes briefly plastic, old patterns loosen, new connections form. Second, and arguably more important, people see their addiction differently. They see what it cost them. They see what they were medicating. They see a version of themselves not yoked to the substance, and they remember that version exists. Whether that change holds depends on what they do in the months that follow. None of this is a substitute for medical care if you're in a serious addiction situation. Ayahuasca interacts badly with SSRIs, MAOIs, and certain heart and blood pressure medications. People with personal or family histories of psychosis or bipolar disorder are generally screened out by responsible retreats. If you're considering plant medicine for addiction, talk to a doctor who won't dismiss the conversation, and choose a retreat with real medical screening, not a questionnaire someone glances at over email. The plant-medicine world has matured, but it's still uneven. For every excellent center run by experienced facilitators and indigenous-trained shamans, there's a glossy website hiding a sketchy operation. Here's what experienced retreat-goers actually look for: Trust your gut on this one. If a retreat's marketing feels more like a wellness brand than a serious medicine container, keep looking. The dieta — the period of dietary and lifestyle restriction before ceremony — isn't optional. Most retreats ask you to cut alcohol, recreational drugs, red meat, pork, fermented foods, processed sugar, and sexual activity for one to two weeks before arrival. Some include cilantro, aged cheese, and a long list of medications. This isn't religious theater. The MAO inhibitors in the vine genuinely interact with tyramine-rich foods and many pharmaceuticals, and the dieta is partly a safety measure. It's also psychological preparation. By the time you arrive, you've already changed your habits. You've already noticed how much you reach for wine at night, or sugar after lunch, or scrolling at 11pm. The brew hasn't started yet and you're already learning. Afterward — and this matters more than the ceremony itself, in my opinion — comes integration. The week or month after a strong ayahuasca experience can feel raw, lit up, sometimes destabilizing. People reconsider jobs, relationships, where they live. Some of these reconsiderations are wise. Some are the medicine talking before it has fully settled. Good practice is to wait a month or two before making any irreversible decision, and to work with an integration therapist or sober friend who can help you sort signal from noise. Honest answer: maybe. Ayahuasca isn't for everyone, and the romanticization of it has done some real damage. People with certain medical conditions shouldn't drink it. People in active crisis often need stabilization before any psychedelic work. People looking for a quick fix tend to come back disappointed — or worse, more lost than they started. But for someone genuinely curious, willing to do the preparation, willing to do the integration, and clear-eyed about the risks — yes, an ayahuasca retreat can be one of the more meaningful weeks of your life. Many people come home with a softer relationship to their own pain, a clearer sense of what matters, and, sometimes, real changes in patterns they'd written off as permanent. Plant medicine isn't a religion, and it isn't a pharmaceutical, and it doesn't need to be either to be worth taking seriously. If you've read this far and something in you is still leaning toward the door marked maybe, take that seriously too. A range of carefully vetted ayahuasca retreats can be browsed on our marketplace here — useful for comparing locations, lineages, and what each container actually offers before you commit. Whatever you decide, decide slowly. The vine has been here for a very long time. It'll wait.
Ibogaine for Opioid Addiction: Could Plant Medicine Crack the Crisis?
The opioid epidemic has outlasted every easy solution thrown at it. Tighter prescribing rules. Naloxone in every paramedic's bag. Methadone clinics. Suboxone scripts. Sober houses. Each one helps somebody — and yet the obituaries keep coming, in rural Ohio, in coastal Maine, in the gated suburbs nobody expected. Somewhere in the middle of that long, exhausting failure, a strange word started showing up in recovery forums and harm-reduction circles: ibogaine. If you've found your way to this article, you probably already know the basics. Ibogaine is a psychoactive compound from the root bark of an African shrub called Tabernanthe iboga. People who've taken it for opioid dependence describe waking up the next day without withdrawal — not white-knuckled, not dope-sick, just… not craving. That's the claim that won't go away. And it's the claim that has Western medicine, very slowly and very awkwardly, starting to pay attention. Let's talk about what ibogaine actually is, what the evidence looks like, what the risks are, and what a person seriously considering a retreat should think through before they book a flight. Iboga has been used ceremonially for centuries by the Bwiti tradition in Gabon and surrounding regions of Central Africa. In that context, it isn't a quick detox tool — it's a rite of passage, a way of meeting the ancestors, of seeing oneself clearly. Doses are large. The experiences last a day or more. People emerge changed, not just chemically but in how they understand who they are. What Western researchers eventually isolated from the bark is an indole alkaloid called ibogaine. Pharmacologically it's a strange creature — it touches opioid receptors, serotonin receptors, NMDA receptors, sigma receptors, and nicotinic receptors all at once. There isn't a single clean mechanism that explains what it does. That polypharmacology is probably part of why it works on addiction at all, and also part of why it carries real cardiac risk. Among the master plants — that loose category of teacher plants like ayahuasca, peyote, and San Pedro — iboga has a particular reputation. People who've sat with several of them often describe iboga as the strictest. Less visionary, more confrontational. A friend who's done both ayahuasca and ibogaine put it bluntly: “Ayahuasca shows you who you could be. Iboga shows you exactly who you are, and doesn't let you look away.” Howard Lotsof, an American who tried ibogaine recreationally in the 1960s while struggling with heroin dependence, noticed something he couldn't explain: his withdrawal symptoms vanished, and his cravings stayed gone for months. He spent decades trying to get medicine to take that observation seriously. Mostly it didn't. But the underground kept the work alive. What the underground figured out, and what a handful of clinical observations have since supported, is that a single high-dose ibogaine session can interrupt opioid dependence in a way that no other pharmaceutical does. Patients walk out of the experience without the weeks of misery that usually accompany kicking opioids. Many describe a long, dreamlike review of their own life — childhood scenes, decisions, regrets, the moments that set the addiction in motion — playing out in front of them while they lie still on a mattress. This is the part that's hard to talk about clinically. The pharmacological reset matters, but the psychological reckoning seems to matter just as much. Ibogaine doesn't feel like recreation. People don't generally want to do it again right away. It's exhausting. And that, paradoxically, is part of what makes it useful for addiction — it doesn't replicate the reward loop that opioids exploit. The honest answer: less than we'd like, and more than skeptics admit. Most of the data on ibogaine comes from observational studies of treatment clinics in Mexico, New Zealand, and a few other jurisdictions where it operates legally or in regulatory gray zones. These studies aren't the gold-standard double-blind trials you'd want — you can't really blind someone to a substance that produces a 24-hour visionary experience — but they're not nothing. What they consistently show: Formal clinical trials are finally beginning to happen. A 2024 Stanford study of ibogaine in military veterans with traumatic brain injury and PTSD produced striking results — significant reductions in PTSD, depression, and anxiety scores that held at follow-up. That study wasn't about opioid addiction specifically, but it broke open the conversation in mainstream medicine in a way two decades of advocacy hadn't. Here's where I have to slow down, because the romance of psychedelic healing tends to gloss over the part that matters most: ibogaine can kill you. Not metaphorically. Cardiac arrhythmia — specifically QT-interval prolongation that can lead to fatal heart rhythms — has caused deaths in ibogaine sessions, including in clinical settings. The deaths are not random. They cluster around predictable risk factors: undiagnosed heart conditions, electrolyte imbalances, interactions with other drugs (including methadone, which has its own QT effects), and clinics that don't do proper medical screening. A responsible ibogaine provider runs an EKG before treatment. They check liver function. They take a careful medication and substance history. They have a cardiologist available or on-call. They use continuous cardiac monitoring during the session. If a provider isn't doing those things, walk away. I don't care how spiritually authentic they sound. I don't care what testimonials they have on their site. The cardiac risk is real and screenable, and any program that treats it casually is a program that will eventually kill somebody. If you're seriously researching this, you should know what a well-run program looks like so you can recognize one when you see it. The pattern across reputable clinics is broadly similar: Costs vary widely. A medically supervised ibogaine program for opioid dependence typically runs between $6,000 and $15,000 USD, depending on country, length of stay, and the level of medical infrastructure. Cheaper than that, you should be asking hard questions about what's being cut. I won't pretend to answer that — nobody on the internet can. But here are the questions I'd want someone in this position to sit with honestly: Ibogaine isn't a magic bullet. It's a powerful interruption — a window. What you build inside that window is the actual recovery. The people I've spoken with who got the most out of it treated the session as the start of the work, not the end of it. The opioid crisis hasn't gone away, and the conventional toolkit, while genuinely lifesaving, isn't enough for everyone. Ibogaine is one of the more promising tools the underground kept alive while the mainstream looked the other way, and it's finally getting the serious research it deserves. For readers who want to take this further, a range of carefully vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Go slowly, ask hard questions, and trust the providers who welcome them.
The Argentine Psychoanalyst Who Took Ayahuasca to the Couch in 1959
Most of the names that get repeated in the current wave of psychedelic history belong to men, and most of them lived north of the equator. So it's worth slowing down for a figure who tends to get edited out of the story: a woman in Buenos Aires who, in the late 1950s, was running LSD-assisted group sessions with food and music in the room — and who flew into the Amazon in 1959 to drink ayahuasca with curanderos before almost anyone in Western medicine had even heard the word. Her name was Luisa Agusta Rebeca Gambier de Álvarez de Toledo. Her colleagues called her Rebe. She was the first woman to preside over the Argentine Psychoanalytical Association, and she happens to have written one of the earliest scientific reports on ayahuasca published outside the Amazon. For readers interested in the deep roots of plant medicine and psychedelics in clinical practice — and how master plants found their way into the modern conversation about addiction, trauma, and soul exploration — her story is essential reading. To understand why Argentina, of all places, became fertile ground for early psychedelic experimentation, you have to understand what the city looked like in the 1940s. After the Spanish Civil War and then the Second World War, Buenos Aires absorbed waves of European intellectuals, doctors, artists, and analysts fleeing fascism. The Argentine Psychoanalytical Association was founded in 1942 in that hothouse of imported ideas, and Freud, Klein, Lacan, and the British object-relations school all got argued over at the same dinner tables. Álvarez de Toledo trained as a physician and got drawn into psychoanalytic theory while still in medical school. By the early 1950s she was working at the Hospicio de la Mercedes, the country's first psychoanalytic institution, alongside the legendary psychiatrist Enrique Pichon-Rivière. Her 1954 paper on the emotional life of the therapist during the session — what we'd now recognise as a precursor to modern conversations about countertransference and presence — is still cited as a classic. She wasn't a fringe figure. She was the establishment. And then, almost as soon as she became APA president in 1956, she organised a working group to experiment with LSD. Sandoz was the source. A representative from the Swiss company supplied the substance and the existing clinical literature, which by then included scattered reports from Europe and a handful of American hospitals. She wasn't even the first in Argentina to publish on it — the psychiatrist Alberto Tallaferro had already documented more than a thousand sessions with LSD and mescaline in 1956, and he sat in on her early work. What's striking, reading her four published articles from 1957 to 1960, is how modern the protocol sounds. The therapists drank the medicine themselves first — sometimes LSD, sometimes mescaline — and wrote up their own experiences in the scientific papers. They considered self-experimentation an ethical prerequisite, not a sideshow. You couldn't sit with a patient through something you hadn't met yourself. She brought two things into the session that weren't standard psychoanalytic furniture: She also refused to leave patients alone. The therapist's job was to build and hold a strong connection — what she'd been arguing for years was the heart of any good analytic relationship, just intensified by the medicine. By 1960, after three years of work, she was running twelve groups, around a hundred patients in total, and concluded that group psychotherapy combined with LSD was, in her words, a really effective method. She also insisted on two facilitators per group, so that if someone went into what she called a generalised psychopathic episode, one therapist could step out with them while the other held the room. Sound familiar? It's the same staffing logic any honest psychedelic retreat uses today. Then came the part of her story that almost nobody outside specialist circles knows. In 1959, Álvarez de Toledo travelled into the Amazon jungle to drink ayahuasca with curanderos. In 1959. Before Burroughs and Ginsberg's Yage Letters had reached a wide audience. Before the Santo Daime had crossed any borders. Before the word ayahuasca meant anything at all to most physicians. She published her account in 1960 as one of the very first scientific articles on the brew. Her method was a hybrid that feels surprisingly contemporary — part ethnography (she wanted to document what the curanderos actually did, in their own terms), part clinical evaluation (she wanted to know whether this could do therapeutic work). She researched how the curanderos understood the experience and what they expected of participants before she ever lifted a cup. She ended up trying ayahuasca twice with two different curanderos. The first ceremony she dismissed almost immediately — the brew had been cut with gasoline (yes, really), the room was small and dirty, the village too close and too noisy. The second time was different. Held in the forest. A curandero who treated her as a colleague and refused payment. She asked specifically to be included in a local group ceremony so she could observe how these things actually unfolded in their natural setting, rather than as a private demonstration for a foreign doctor. Her own description of the experience is worth quoting because it's so unguarded — a trained analyst writing without any of the defensive posture you'd expect from a 1960 medical journal: The curandero himself vomited, she noted, as an invitation to the others. This worried her — in her psychoanalytic frame, vomiting and diarrhea were defensive responses to the fear of the unknown. The villagers reassured her. Then her own nausea came, dry and without release, and the trance took her over completely beneath the icaros being sung around her. Walking back to the village afterwards, she described seeing the earth and plants and her own body emitting bluish waves spreading outward, lights appearing and going out around her, a deep euphoria in the presence of such beauty. She walked, uncertain, on a very soft earth. Her clinical summary afterwards was characteristically honest: she felt the observation had been disturbed by her own defenses and by her lack of the ritual language, which prevented her from fully grasping what the masters were actually doing therapeutically. She wasn't claiming mastery. She was naming the gap. It's easy to read history like this as colourful background, but it bears directly on choices people are making right now. The current wave of interest in plant medicine for addiction, depression, and trauma sometimes presents itself as brand new. It isn't. Álvarez de Toledo and her colleagues had already worked out, three generations ago, several of the principles that any reputable retreat should still be following: What strikes me, reading her papers now, is how much of the current psychedelic-assisted therapy world is reinventing wheels she'd already drawn. The careful preparation. The continuous presence. The integration sessions. The respect for group dynamics. She got there in heels in Buenos Aires in 1957 and confirmed it under icaros in the Amazon in 1959. Álvarez de Toledo died in 1990, just as MAPS was being founded in California and the modern revival was beginning to stir. She didn't live to see ayahuasca become an international phenomenon, didn't watch psilocybin trials at Johns Hopkins, didn't read the headlines about ibogaine for opioid addiction. But the through-line is hers as much as anybody's: a working clinician who took these substances seriously as therapeutic tools, treated traditional knowledge as knowledge rather than folklore, and held herself to the same rigour with mescaline and ayahuasca that she held herself to with her analytic patients. For anyone weighing whether to sit in ceremony, her example offers something more useful than enthusiasm. It offers a standard. Does the place you're considering treat preparation seriously? Are the facilitators trained, present, and willing to talk about their own relationship with the medicine? Is there real integration support afterwards? Those questions aren't new. They've just been waiting for us to ask them again. If reading this has sharpened your curiosity, a range of carefully vetted ayahuasca and plant-medicine retreats can be explored on our marketplace here — a useful place to start when you want to see what genuinely thoughtful facilitation looks like in practice today.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
